​

Protagenic Therapeutics Stock (NASDAQ:PTIX)

OwnershipFinancialsChart

Previous Close

$0.53

52W Range

$0.25 - $6.20

50D Avg

$0.62

200D Avg

$1.51

Market Cap

$1.23M

Avg Vol (3M)

$5.55K

Beta

0.47

Div Yield

-

PTIX Company Profile

Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

Apr 27, 2021

Website

PTIX Performance

PTIX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-5.70M$-4.53M$-3.56M
Net Income$-5.53M$-5.00M$-3.60M
EBITDA$-5.70M$-4.50M$-3.42M
Basic EPS$-1.13$-1.15$-0.83
Diluted EPS$-1.13$-1.15$-0.83

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Apr 01, 24 | 4:30 PM

Peer Comparison

TickerCompany
PBMPsyence Biomedical Ltd.
SPRCSciSparc Ltd.
CARMCarisma Therapeutics, Inc.
ARTLArtelo Biosciences, Inc.
GTBPGT Biopharma, Inc.
REVBRevelation Biosciences, Inc.
SLXNSilexion Therapeutics Ltd.
INDPIndaptus Therapeutics, Inc.